| Name | Title | Contact Details |
|---|
KOTYS is a Powell, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
IlluminOss Medical is a privately-held, commercial stage medical device company focused on designing, developing and marketing orthopedic fracture repair products that leverage its proprietary bone stabilization technology, IlluminOss System. This minimally invasive technology allows for fracture fixation through patient specific intramedullary implants. The IlluminOss System utilizes a light-curable polymer, contained within an expandable balloon catheter to achieve bone stabilization. The revolutionary procedure is made through a small percutaneous surgical approach providing patients and clinicians with a fast, patient-specific, method of orthopedic bone stabilization. The company currently markets its products in the EU under a CE Mark for approved clinical applications through both a direct sales force and distribution networks. Founded in 2007, IlluminOss is headquartered in East Providence, RI, and funded by Flare Capital Partners, New Leaf Venture Partners, Tekla Capital, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and Slater Technology.
Surmodics partners with the world`s leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. Following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. Throughout its transformation, Surmodics` mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges
Surgical Equipment People, The is a Knoxville, TN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Vermillion`s vision is to become a recognized leader in the advancement of women`s health by providing innovative methods to detect, monitor and manage the treatment of gynecologic cancers and other related diseases. We will develop and commercialize high-value, multi-marker, diagnostic tests which address unmet needs in gynecologic oncology and women’s health. We will accomplish our mission through internal development, targeted acquisitions, and collaborations with leading scientific and clinical institutions. Our global commercial efforts will include direct marketing and sales activities as well as partnerships with leading companies in women’s health.